Insulin Syringes Market Size

Global Insulin Syringes Market size was valued at USD 1.7 billion in 2023 and is poised to grow from USD 1.77 billion in 2024 to USD 2.46 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The rapid rise in diabetes prevalence, especially type 2 diabetes, is a major driver of the global insulin syringes market. Contributing factors include sedentary lifestyles, poor dietary habits, urbanization, and increasing obesity rates across both developed and developing nations. According to the International Diabetes Federation, the number of adults with diabetes is expected to grow from 537 million in 2021 to 783 million by 2045. With insulin therapy becoming a must for millions of patients, the need for efficient and affordable insulin delivery systems such as syringes remains on the rise, especially in low-resource environments where state-of-the-art devices would be out of reach.

The key trends driving the global insulin syringes sector, are the evolving priorities of major pharmaceutical companies, such as Novo Nordisk, which are phasing out older, less profitable insulin delivery options like human insulin pens in favor of newer, high-margin drugs like GLP-1 receptor agonists. This shift in strategy leaves many patients, especially in low- and middle-income nations, with fewer relatively affordable insulin delivery options. Subsequently, these patient groups are turning back towards conventional insulin syringes, which are still ubiquitous and inexpensive. This situation is driving syringe demand, particularly in healthcare systems with limited availability of newer treatments or the supporting infrastructure for pen or pump technology.

How is AI Transforming the Insulin Syringes Market?

Artificial intelligence (AI) is transforming the global insulin syringes market by hastening the shift towards automated insulin delivery systems. AI-based technologies, including hybrid closed-loop systems or "artificial pancreas" devices, couple continuous glucose monitoring with insulin pumps to automate insulin administration. The systems minimize the occurrence of manual insulin injections, hence less frequent use of conventional syringes. For example, the UK's National Health Service (NHS) has started distributing artificial pancreas devices to hundreds of thousands of type 1 diabetes sufferers with the aim of improving quality of life and lowering complications. With AI-facilitated solutions available increasingly more widely, particularly in the developed world, demand for traditional insulin syringes will likely fall, leading to market movement towards advanced, automated means of insulin delivery.

In August 2024, Insulet Corporation received FDA approval for its Omnipod 5 Automated Insulin Delivery System for adults with Type 2 diabetes. This tubeless, AI-controlled insulin pump combines with continuous glucose monitoring to adjust insulin delivery automatically every five minutes, minimizing the injections. International launches of this system have noticeably increased the sales of Insulet, with Q3 2024 seeing a rise of 26% due to strong international demand.